Bevacizumab combination safe, effective for endometrial cancer

The addition of postoperative bevacizumab to chemotherapy and pelvic intensity-modulated radiotherapy demonstrated high survival rates and was well tolerated for patients with high-risk endometrial cancer, according to prospective study results. “This prospective phase 2 trial demonstrated that using pelvic IMRT concurrently with bevacizumab and cisplatin is feasible and has low rates of bevacizumab-specific toxicities,” Akila N. Viswanathan, MD, MPH, senior physician and director of gynecologic radiation oncology at Dana-Farber Cancer Institute and an associate professor of radiation oncology at Harvard Medical School, told HemOnc Today.